Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 98

1.

Immunomodulatory properties of mesenchymal stem cell in experimental arthritis in rat and mouse models: A systematic review.

Hynes K, Bright R, Proudman S, Haynes D, Gronthos S, Bartold M.

Semin Arthritis Rheum. 2016 Mar 7. pii: S0049-0172(16)00088-3. doi: 10.1016/j.semarthrit.2016.02.008. [Epub ahead of print] Review.

PMID:
27105756
2.

Reduced corticosteroid-binding globulin cleavage in active rheumatoid arthritis.

Nenke MA, Lewis JG, Rankin W, McWilliams L, Metcalf RG, Proudman SM, Torpy DJ.

Clin Endocrinol (Oxf). 2016 Apr 8. doi: 10.1111/cen.13081. [Epub ahead of print]

PMID:
27061835
3.

Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.

Owen C, Ngian GS, Elford K, Moore O, Stevens W, Nikpour M, Rabusa C, Proudman S, Roddy J, Zochling J, Hill C, Sturgess A, Tymms K, Youssef P, Sahhar J.

Clin Exp Rheumatol. 2016 Mar 24. [Epub ahead of print]

PMID:
27049330
4.

Active Foot Synovitis in Patients with Rheumatoid Arthritis: Patients with Foot Synovitis in Apparent Remission have Unstable Remission Status, Radiographic Progression and Worse Functional Outcomes.

Wechalekar MD, Lester S, Hill CL, Lee A, Rischmueller M, Smith MD, Walker JG, Proudman SM.

Arthritis Care Res (Hoboken). 2016 Mar 18. doi: 10.1002/acr.22887. [Epub ahead of print]

PMID:
26991415
5.

Drug-induced toxicity and patient reported outcomes in rheumatoid arthritis patients following intensive treated-to-target strategy: does ceasing therapy due to toxicity worsen outcomes in long term?

Wabe N, Sorich MJ, Wechalekar MD, Cleland LG, McWilliams L, Lee A, Hall C, Spargo L, Metcalf R, Proudman SM, Wiese MD.

Int J Clin Pract. 2016 Apr;70(4):340-50. doi: 10.1111/ijcp.12785. Epub 2016 Mar 14.

PMID:
26987888
6.

Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia.

Hopkins AM, Proudman SM, Vitry AI, Sorich MJ, Cleland LG, Wiese MD.

Med J Aust. 2016 Feb 1;204(2):64-8.

PMID:
26821102
7.

A model-based evaluation of single metrics for discriminating changes in rheumatoid arthritis disease activity.

Wojciechowski J, Wiese MD, Proudman SM, Foster DJ, Upton RN.

Br J Clin Pharmacol. 2016 Jan 26. doi: 10.1111/bcp.12891. [Epub ahead of print]

PMID:
26810813
8.

The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.

Khanna D, Berrocal VJ, Giannini EH, Seibold JR, Merkel PA, Mayes MD, Baron M, Clements PJ, Steen V, Assassi S, Schiopu E, Phillips K, Simms RW, Allanore Y, Denton CP, Distler O, Johnson SR, Matucci-Cerinic M, Pope JE, Proudman SM, Siegel J, Wong WK, Wells AU, Furst DE.

Arthritis Rheumatol. 2016 Feb;68(2):299-311. doi: 10.1002/art.39501.

PMID:
26808827
9.

The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.

Khanna D, Berrocal VJ, Giannini EH, Seibold JR, Merkel PA, Mayes MD, Baron M, Clements PJ, Steen V, Assassi S, Schiopu E, Phillips K, Simms RW, Allanore Y, Denton CP, Distler O, Johnson SR, Matucci-Cerinic M, Pope JE, Proudman SM, Siegel J, Wong WK, Wells AU, Furst DE.

Arthritis Care Res (Hoboken). 2016 Feb;68(2):167-78. doi: 10.1002/acr.22804.

PMID:
26806474
10.

Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritis.

Wabe N, Sorich MJ, Wechalekar MD, Cleland LG, McWilliams L, Lee A, Spargo L, Metcalf R, Hall C, Proudman SM, Wiese MD.

Int J Rheum Dis. 2015 Dec 22. doi: 10.1111/1756-185X.12816. [Epub ahead of print]

PMID:
26692459
11.

Fish oil in knee osteoarthritis: a randomised clinical trial of low dose versus high dose.

Hill CL, March LM, Aitken D, Lester SE, Battersby R, Hynes K, Fedorova T, Proudman SM, James M, Cleland LG, Jones G.

Ann Rheum Dis. 2016 Jan;75(1):23-9. doi: 10.1136/annrheumdis-2014-207169. Epub 2015 Sep 9.

PMID:
26353789
12.

Cost savings with a new screening algorithm for pulmonary arterial hypertension in systemic sclerosis.

Quinlivan A, Thakkar V, Stevens W, Morrisroe K, Prior D, Rabusa C, Youssef P, Gabbay E, Roddy J, Walker JG, Zochling J, Sahhar J, Nash P, Lester S, Rischmueller M, Proudman SM, Nikpour M.

Intern Med J. 2015 Nov;45(11):1134-40. doi: 10.1111/imj.12890.

PMID:
26337683
13.

Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects.

Wodkowski M, Hudson M, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD, Tatibouet S, Wang M; Canadian Scleroderma Research Group (CSRG); Australian Scleroderma Interest Group (ASIG); Genetics versus Environment in Scleroderma Outcome Study (GENISOS), Baron M, Fritzler MJ.

Autoimmunity. 2015;48(8):542-51. doi: 10.3109/08916934.2015.1077231. Epub 2015 Aug 31.

PMID:
26334795
14.

Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.

Hopkins AM, Wiese MD, Proudman SM, O'Doherty CE, Upton RN, Foster DJ.

Br J Clin Pharmacol. 2016 Jan;81(1):113-23. doi: 10.1111/bcp.12760. Epub 2015 Oct 28.

PMID:
26331989
15.

Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival.

Wodkowski M, Hudson M, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD, Wang M, Baron M, Fritzler MJ; Canadian Scleroderma Research Group (CSRG); Australian Scleroderma Cohort Study (ASCS); Genetics versus Environment in Scleroderma Outcome Study (GENISOS).

Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S131-5. Epub 2015 Aug 27.

PMID:
26315678
16.

Plasma n-3 fatty acids and clinical outcomes in recent-onset rheumatoid arthritis.

Proudman SM, Cleland LG, Metcalf RG, Sullivan TR, Spargo LD, James MJ.

Br J Nutr. 2015 Sep 28;114(6):885-90. doi: 10.1017/S0007114515002718. Epub 2015 Aug 18.

PMID:
26283657
17.

Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis.

Patterson KA, Roberts-Thomson PJ, Lester S, Tan JA, Hakendorf P, Rischmueller M, Zochling J, Sahhar J, Nash P, Roddy J, Hill C, Nikpour M, Stevens W, Proudman SM, Walker JG.

Arthritis Rheumatol. 2015 Dec;67(12):3234-44. doi: 10.1002/art.39316.

PMID:
26246178
18.

Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease.

Moore OA, Proudman SM, Goh N, Corte TJ, Rouse H, Hennessy O, Morrisroe K, Thakkar V, Sahhar J, Roddy J, Youssef P, Gabbay E, Nash P, Zochling J, Stevens W, Nikpour M.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S111-6. Epub 2015 Aug 5.

PMID:
26243401
19.

Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients.

Hopkins AM, Wiese MD, Proudman SM, O'Doherty CE, Foster D, Upton RN.

CPT Pharmacometrics Syst Pharmacol. 2015 Jun;4(6):362-71. doi: 10.1002/psp4.46. Epub 2015 Jun 15.

20.

Musculoskeletal Manifestations of Systemic Sclerosis.

Morrisroe KB, Nikpour M, Proudman SM.

Rheum Dis Clin North Am. 2015 Aug;41(3):507-18. doi: 10.1016/j.rdc.2015.04.011. Epub 2015 May 26. Review.

PMID:
26210132
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk